In March 2013, China’s Ministry of Health (MOH) released the new essential drug list (the “2012 EDL”). Significant changes are outlined in the newly released documents; such change will undoubtedly assert great influence over future development prospects of multinational corporations (MNCs) in China. To help MNCs understand and navigate the newly announced policies, IMS Consulting Group in China has executed a deep-dive analysis of EDL updated and supporting policy evolvements and explored their impact to MNCs.
In this study, MNCs refer to 34 member companies of R&D-based Pharmaceutical Association Committee (RDPAC). Sales data of tier 2 and 3 hospitals comes from IMS Midas database (which collects hospital purchasing information from hospitals with 100+ beds and projects to national tier with advanced statistical models).